iPSC-CL

Phase 1Biologic

HHeartWorks, Inc.

iPSC-CL is one of 41 biologic programs targeting Congenital Heart Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congenital Heart DiseaseActive, not recruiting

Congenital Heart DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Congenital Heart Disease

#DrugCompanyPhaseTrials

Tracleer

Johnson & Johnson

Approved

1 2

Remodulin

Theo-Dur

Intropin

Opsumit

Jardiance

1 7

Pepcid

KKenvue Brands

Approved

1 8

Feraheme

AAzurity Pharmaceuticals

Approved

1 9

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Decadron

AAspen Global Incorporated

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Congenital Heart Disease

NCT05647213

Clinical

Trials by Indication[1]

Congenital Heart Disease1 trial

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Recruiting·HHeartWorks, Inc.·Phase 1·NCT05647213·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for iPSC-CL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iPSC-CL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iPSC-CL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HeartWorks, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: HHeartWorks, Inc.

iPSC-CL

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Congenital Heart Disease1 trial

References

Drug Info

Quick Facts

Related News